Dr. Howard Hochster Provides Thoughts on the Clinical Progress of Enhertu in GI Cancers

Dr. Hochster provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers such as gastric and colorectal cancer presented at ASCO20.

Trials in Progress Presented at ASCO GI 2021

Dr. Zev A. Wainberg provides updates on key trials in progress presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2021.

Bi-Specific Antibodies in HER2+ Gastric Cancer

Dr. Hyun C. Chung provides an overview of ongoing studies in patients with HER2+ gastric cancer, including the use of novel immunotherapy and bi-specific antibodies.


Practice-Changing GI Cancer Highlights From Virtual ASCO 2020

Dr. John L. Marshall discusses various GI cancer highlights from virtual ASCO 2020.

Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer

Dr. David H. Ilson discusses gastric cancer in this CME/MOC activity titled “Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer.”

ESMO20 YO for YO: Highlights on Upper GI Tumors

In this podcast, Dr. Claudia Cardone interviews Dr. Elizabeth Smyth for highlights on upper gastrointestinal tumors, following ESMO 2020 Virtual Congress.

Hear the expert panel offer their perspectives on the latest studies evaluating therapies targeting FGFR2 and HER2 in both gastric cancer and cholangiocarcinoma and other studies from ASCO GI 2021.


Dr Ashwani Rajput discusses treating patients with gastrointestinal cancers, specifically colorectal cancer and pancreatic cancer, as well as the importance of clinical trials...

ASCO GI Review and The Impact of Clinical Trials

Dr. Alok Khorana, Director of The Gastrointestinal Malignancies Program and Vice Chair for Career Academic Development at Cleveland Clinic, discusses some of his key takeaways from ASCO 2020.

Treatment Advances in Gastrointestinal Stromal Tumor With Shreyaskumar Patel, MD

Treatment for GIST has seen exciting progress this year, with two new FDA approvals for metastatic disease.

More From #GI21: Findings in Gastric Cancer, Cholangiocarcinoma, and Pancreatic Cancer

This week, we’re back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDH

Dr Shitara Talks Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer

Dr. Kohei Shitara discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results following the DESTINY-Gastric01 study.

Latest News in Gastric Cancer From ASCO GI

Dr. Geoffrey Y. Ku explores key updates from the ASCO GI Cancers Symposium, including a bispecific antibody in HER2-positive tumors, as well as the approval of trastuzumab deruxtecan.

ASCO GI 2021: HER2-Positive Gastric Cancer, POLO and Key Trials in Progress

Dr. Lola A. Fashoyin-Aje outlines her top picks from 2021 ASCO GI Cancers Symposium including a talk evaluating key recent milestones in the treatment of HER2-positive gastric cancers...

DESTINY-Gastric03: Trastuzumab Deruxtecan in HER2-Overexpressing Gastric Cancer

Dr. Yelena Y. Janjigian discusses the ongoing DESTINY-Gastric03 study, a Phase Ib/II, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan monotherapy and...

ATTRACTION-4: Nivolumab Plus Chemotherapy for Gastric or Gastroesophageal Cancer

Prof. Narikazu Boku speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the ATTRACTION-4 study results.

Personalizing Gastric Cancer Care With HER2-Targeted and Other Novel Therapies

Discussion on gastric cancer in this CME/MOC activity titled: Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

GASTHER2: Trastuzumab for Advanced Gastric Cancer

Dr. Rachel Riechelmann outlines the rationale behind the GASTHER2 study evaluating trastuzumab for patients with advanced gastric cancer with HER2+ expression in circulating tumour cells.


This episode highlights the new indication for Enhertu regarding HER2+ GI cancer.


Dr Josep Tabernero gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer.


These experts examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into...


An expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses...


Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers.

Dr. Andres Cervantes Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and new advancements in treatment of HER2+ gastric cancer.



This podcast covers the findings with three study authors from the virtual 2021 ASCO GI Cancers Symposium.


 Geoffrey Ku, MD, and Robert Figlin, MD, discuss recent clinical developments in gastric and esophageal cancer.


Drs Hofland and Massacesi discuss the company’s partnerships with Daiichi Sankyo in developing a very targeted drug  for the treatment of patients with HER2+ advanced gastric cancer.

ESMO-Magnitude of Clinical Benefit Scale of Adjuvant Colon Cancer Trials and Meta-Analyses

Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale serves to grade therapies with curative intent.


In this podcast new, practice-changing research in GI cancer is considered.

Dr. S. Lindsey Davis Highlights Key Abstracts on GI Cancers from the #ASCO20 Virtual Scientific Program

Dr. S. Lindsey Davis, medical oncologist and assistant professor at the University of Colorado Cancer Center, highlights key abstracts on GI cancers that were featured at ASCO20.


A discussion of various treatments and therapies for gastric cancer, including HER2+ advanced gastric/GEJ cancer.

This podcast discusses the JACOB trial published on pertuzumab for HER2-positive gastric cancer.

This podcast briefly reviews the historical gastric cancer classifications and explains how this has drastically changed over the past 5-10 years with the advent of next-generation...

source list reference

RGB(78, 191, 50)
rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb (132, 101, 173)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
RGB(171, 29, 196)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (132, 101, 173)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb (132, 101, 173)
rgb(181, 112, 164)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
rgb(245, 111, 66)
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(11, 160, 224)
rgb(66, 135, 245)
rgb(101, 11, 212)
rgb(169, 196, 201)
rgb(125, 127, 130)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(110, 57, 65)
rgb(217, 7, 192)
rgb (247, 7, 79)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
rgb(214, 139, 202)
rgb (132, 101, 173)
rgb(10, 191, 137)